相似文献
1
Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma.
World J Gastroenterol. 2015 Apr 7;21(13):3860-6. doi: 10.3748/wjg.v21.i13.3860.
2
Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma.
World J Gastroenterol. 2015 Jul 21;21(27):8249-55. doi: 10.3748/wjg.v21.i27.8249.
3
Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma.
Hepatobiliary Pancreat Dis Int. 2013 Jun;12(3):251-5. doi: 10.1016/s1499-3872(13)60041-7.
4
Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma.
World J Gastroenterol. 2013 Dec 21;19(47):8861-6. doi: 10.3748/wjg.v19.i47.8861.
5
Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma.
World J Gastroenterol. 2014 May 28;20(20):6006-12. doi: 10.3748/wjg.v20.i20.6006.
6
Hepatitis B viral load affects prognosis of hepatocellular carcinoma.
World J Gastroenterol. 2014 Sep 14;20(34):12039-44. doi: 10.3748/wjg.v20.i34.12039.
7
Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma.
Oncotarget. 2017 Feb 28;8(9):15047-15056. doi: 10.18632/oncotarget.14789.
8
Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma.
J Hepatobiliary Pancreat Sci. 2012 Nov;19(6):685-96. doi: 10.1007/s00534-011-0489-z.
9
Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
J Gastroenterol Hepatol. 2011 Sep;26(9):1380-8. doi: 10.1111/j.1440-1746.2011.06776.x.
10
Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.
J Gastroenterol Hepatol. 2007 Nov;22(11):1929-35. doi: 10.1111/j.1440-1746.2006.04707.x.
引用本文的文献
1
Roadmap for HCC Surveillance and Management in the Asia Pacific.
Cancers (Basel). 2025 Jun 10;17(12):1928. doi: 10.3390/cancers17121928.
2
Efficacy and safety of cinobufacin-based combination therapy for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials.
Discov Oncol. 2025 May 8;16(1):703. doi: 10.1007/s12672-025-02501-7.
3
The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients.
Front Immunol. 2024 Nov 27;15:1480520. doi: 10.3389/fimmu.2024.1480520. eCollection 2024.
4
Tenofovir versus Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma After FOLFOX-Hepatic Arterial Infusion Chemotherapy.
J Hepatocell Carcinoma. 2023 Nov 30;10:2117-2132. doi: 10.2147/JHC.S436062. eCollection 2023.
5
Low-dose nivolumab in advanced hepatocellular carcinoma.
BMC Cancer. 2022 Nov 8;22(1):1153. doi: 10.1186/s12885-022-10271-6.
6
Novel directions of precision oncology: circulating microbial DNA emerging in cancer-microbiome areas.
Precis Clin Med. 2022 Feb 3;5(1):pbac005. doi: 10.1093/pcmedi/pbac005. eCollection 2022 Mar.
7
Reporting and Performance of Hepatocellular Carcinoma Risk Prediction Models: Based on TRIPOD Statement and Meta-Analysis.
Can J Gastroenterol Hepatol. 2021 Aug 2;2021:9996358. doi: 10.1155/2021/9996358. eCollection 2021.
8
Hepatitis B virus inhibits the expression of complement C3 and C4, and .
Oncol Lett. 2018 May;15(5):7459-7463. doi: 10.3892/ol.2018.8223. Epub 2018 Mar 9.
9
Viral Oncology: Molecular Biology and Pathogenesis.
J Clin Med. 2017 Nov 29;6(12):111. doi: 10.3390/jcm6120111.
10
Treatment Options in Hepatitis C.
Dtsch Arztebl Int. 2017 Jan 9;114(1-02):11-21. doi: 10.3238/arztebl.2017.0011.
本文引用的文献
1
Risk factors for hepatocellular carcinoma.
Clin Liver Dis (Hoboken). 2013 Jan 23;1(6):180-182. doi: 10.1002/cld.111. eCollection 2012 Dec.
2
[Expert consensus on antiviral therapy to treat hepatitis B/C virus-related hepatocellular carcinoma].
Zhonghua Gan Zang Bing Za Zhi. 2014 May;22(5):321-6.
3
Current management of hepatocellular carcinoma.
Gastroenterol Hepatol (N Y). 2014 Mar;10(3):153-61.
4
Epigenetics in liver disease.
Hepatology. 2014 Oct;60(4):1418-25. doi: 10.1002/hep.27131. Epub 2014 May 7.
5
Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation.
World J Gastroenterol. 2013 Dec 28;19(48):9189-97. doi: 10.3748/wjg.v19.i48.9189.
6
Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients.
Clin Mol Hepatol. 2013 Sep;19(3):273-9. doi: 10.3350/cmh.2013.19.3.273. Epub 2013 Sep 30.
7
Does anti-HBV therapy benefit the prognosis of HBV-related hepatocellular carcinoma following hepatectomy?
Ann Surg Oncol. 2014 Mar;21(3):1010-5. doi: 10.1245/s10434-013-3320-z.
8
Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis.
PLoS One. 2013 Sep 17;8(9):e61361. doi: 10.1371/journal.pone.0061361. eCollection 2013.
9
A systematic review and meta-analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis-related hepatocellular carcinoma.
J Viral Hepat. 2013 Oct;20(10):729-43. doi: 10.1111/jvh.12096. Epub 2013 Apr 16.
10
Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study.
J Clin Oncol. 2013 Oct 10;31(29):3647-55. doi: 10.1200/JCO.2012.48.5896. Epub 2013 Sep 3.
Zotero 插件